Trial Profile
A Phase 1, Open-label Study to Investigate the Absorption, Metabolism and Excretion of [14C] Anlotinib in Patients With Advanced Cancer Patients
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 May 2019
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary)
- Indications Colorectal cancer; Non-small cell lung cancer; Renal cell carcinoma; Soft tissue sarcoma; Solid tumours
- Focus Pharmacokinetics
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 27 Apr 2019 Status changed from active, no longer recruiting to completed.
- 23 Apr 2017 Status changed from recruiting to active, no longer recruiting.
- 25 Apr 2016 Status changed from not yet recruiting to recruiting.